News
ENTO
0.5144
+1.86%
0.0094
Entero Therapeutics appoints interim CEO
Seeking Alpha · 2d ago
Entero Therapeutics names Richard Paolone as interim CEO
TipRanks · 2d ago
Press Release: Entero Therapeutics Appoints Richard Paolone as CEO
Dow Jones · 2d ago
Weekly Report: what happened at ENTO last week (0203-0207)?
Weekly Report · 02/10 09:32
Entero Therapeutics secures $2M revolving loan, appoints three new directors
TipRanks · 02/07 20:40
Entero Therapeutics Secures $2M Loan; Appoints Three New Board Members After Replacing 3 Of 5 Of Its Directors
Benzinga · 02/07 20:23
ENTERO THERAPEUTICS SECURES $2 MILLION REVOLVING LOAN; APPOINTS THREE NEW BOARD MEMBERS
Reuters · 02/07 20:22
Entero Therapeutics Announces Board of Directors Restructuring
TipRanks · 02/06 22:09
Weekly Report: what happened at ENTO last week (0127-0131)?
Weekly Report · 02/03 09:34
Weekly Report: what happened at ENTO last week (0120-0124)?
Weekly Report · 01/27 09:34
Weekly Report: what happened at ENTO last week (0113-0117)?
Weekly Report · 01/20 09:32
Weekly Report: what happened at ENTO last week (0106-0110)?
Weekly Report · 01/13 09:33
Weekly Report: what happened at ENTO last week (1230-0103)?
Weekly Report · 01/06 09:35
Weekly Report: what happened at ENTO last week (1223-1227)?
Weekly Report · 12/30/2024 09:33
Weekly Report: what happened at ENTO last week (1216-1220)?
Weekly Report · 12/23/2024 09:35
Weekly Report: what happened at ENTO last week (1209-1213)?
Weekly Report · 12/16/2024 09:35
Weekly Report: what happened at ENTO last week (1202-1206)?
Weekly Report · 12/09/2024 09:34
Weekly Report: what happened at ENTO last week (1125-1129)?
Weekly Report · 12/02/2024 09:35
ENTERO THERAPEUTICS INC: EXPECT TO CONTINUE TO, EXPLORE VARIOUS POTENTIAL STRATEGIES AVAILABLE TO CO
Reuters · 11/27/2024 22:09
ENTERO THERAPEUTICS : NOTICE INFORMED IMMUNOGENX THAT ONE OR MORE EVENTS OF DEFAULT UNDER CREDIT AGREEMENT WERE EXISTING AND CONTINUING
Reuters · 11/27/2024 22:09
More
Webull provides a variety of real-time ENTO stock news. You can receive the latest news about Entero Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About ENTO
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for multiple GI conditions, including gastroparesis, and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. The Company also intends to develop Niclosamide, an oral small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.